The Society of Nuclear Drugs and Molecular Imaging (SNMMI) and the European Affiliation of Nuclear Drugs (EANM) have issued a brand new process customary/apply guideline for estrogen receptor imaging of breast most cancers sufferers utilizing FES PET. The usual/guideline, printed forward of print in The Journal of Nuclear Drugs, is meant to help physicians in recommending, performing, decoding, and reporting the outcomes of 18F-FES PET research for sufferers with breast most cancers.
Greater than two million girls worldwide are identified with breast most cancers every year. The estrogen receptor (ER) is a major contributor to breast most cancers formation and development and, as such, is a crucial goal for remedy. Roughly 70 p.c of breast cancers will specific ER, and the dedication of ER expression by tissue evaluation is a part of the usual of take care of these newly identified breast most cancers.
A number of research counsel that 18F-FES PET-;which is authorized for scientific use in France and the United States-;affords benefits in assessing tumor ER expression, predicting response to ER-targeted therapies, and clarifying equivocal staging and restaging leads to sufferers with ER-expressing cancers. It might even be useful in staging invasive lobular breast most cancers and low-grade ER-expressing invasive ductal cancers and, in some circumstances, could also be an alternative to biopsy.
The process guideline/apply customary contains data on frequent scientific indications, process specs, affected person choice and preparation, tracer administration and imaging, and imaging interpretation and reporting. It additionally presents standardized high quality management, high quality assurance, and imaging procedures for 18F-FES PET.
“Precision, accuracy, repeatability, and reproducibility for each scientific administration of sufferers and for the usage of 18F-FES in multicenter trials is essential,” emphasize the authors. “The supply of a standardized imaging process will assist to advertise the suitable use of 18F-FES PET and improve subsequent analysis.”
SNMMI/EANM periodically outline new requirements/tips for nuclear drugs apply to assist advance the science of nuclear drugs and to ship efficient and secure medical care to sufferers. Every customary/guideline, representing a coverage assertion by the SNMMI/EANM, undergoes a radical consensus course of wherein it’s subjected to intensive evaluate.
This text was printed on-line in December 2023.
Supply:
Journal reference:
Mankoff, D., et al. (2023). Abstract: SNMMI Process Normal/EANM Observe Guideline for Estrogen Receptor Imaging of Sufferers with Breast Most cancers Utilizing 16α-[18F]Fluoro-17β-Estradiol PET. Journal of Nuclear Drugs. doi.org/10.2967/jnumed.123.266938.
